Opinion

Video

Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Video content above is prompted by the following:

  • Can you talk about switching from dupilumab and other RWD with IL-13 agents in AD?
Related Videos
After the Smoke: Wildfire Cleanup & Air Quality Concerns with Afif El-Hasan, MD
Atopic Disease Hypersensitivity Reactions Vary by Biologic Type with Valerie Jaroenpuntaruk, MD
5 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Omega-3 Fatty Acids Reduce Atopic Dermatitis Risk Despite Genetic Predispositions
February 25th 2025

Omega-3 Fatty Acids Reduce Atopic Dermatitis Risk Despite Genetic Predispositions

Tim Smith
HCPLive 5 Stories in Under 5: Week of 02/16
February 24th 2025

HCPLive 5 Stories in Under 5: Week of 02/16

HCPLive Editorial Staff
Hayley Baker, MD I Credit: X
February 25th 2025

Pediatric Obesity Linked to Increased Risk of New-Onset Allergic Rhinitis

Chelsie Derman
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis | Image Credit: US Food and Drug Administration
February 25th 2025

FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis

Connor Iapoce
Adding 1 Miligram to Standard Minoxidil Treatment Ineffective for Lichen Planopilaris
February 25th 2025

Adding 1 Miligram to Standard Minoxidil Treatment Ineffective for Lichen Planopilaris

Tim Smith
© 2025 MJH Life Sciences

All rights reserved.